Clin Mol Hepatol.
2025 Jan;31(1):e67-e69. 10.3350/cmh.2024.0744.
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- Affiliations
-
- 1Department of Infectious Diseases, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
- 2Central Laboratories, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
- KMID: 2563462
- DOI: http://doi.org/10.3350/cmh.2024.0744
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
- TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
- Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
- Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
